- Home
- WYY vs SKYE Comparison
WYY vs SKYE Comparison
Compare WYY & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYY
- SKYE
- Stock Information
- Founded
- WYY 1991
- SKYE 2012
- Country
- WYY United States
- SKYE United States
- Employees
- WYY N/A
- SKYE N/A
- Industry
- WYY EDP Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- WYY Technology
- SKYE Health Care
- Exchange
- WYY Nasdaq
- SKYE Nasdaq
- Market Cap
- WYY 48.9M
- SKYE 46.5M
- IPO Year
- WYY 1998
- SKYE N/A
- Fundamental
- Price
- WYY $6.80
- SKYE $1.55
- Analyst Decision
- WYY Strong Buy
- SKYE Strong Buy
- Analyst Count
- WYY 3
- SKYE 5
- Target Price
- WYY $8.67
- SKYE $14.75
- AVG Volume (30 Days)
- WYY 74.1K
- SKYE 568.6K
- Earning Date
- WYY 11-13-2025
- SKYE 11-10-2025
- Dividend Yield
- WYY N/A
- SKYE N/A
- EPS Growth
- WYY N/A
- SKYE N/A
- EPS
- WYY N/A
- SKYE N/A
- Revenue
- WYY $144,421,640.00
- SKYE N/A
- Revenue This Year
- WYY $9.07
- SKYE N/A
- Revenue Next Year
- WYY $13.20
- SKYE N/A
- P/E Ratio
- WYY N/A
- SKYE N/A
- Revenue Growth
- WYY 16.25
- SKYE N/A
- 52 Week Low
- WYY $2.19
- SKYE $1.14
- 52 Week High
- WYY $7.55
- SKYE $5.96
- Technical
- Relative Strength Index (RSI)
- WYY 59.68
- SKYE 38.64
- Support Level
- WYY $6.33
- SKYE $1.42
- Resistance Level
- WYY $7.19
- SKYE $1.60
- Average True Range (ATR)
- WYY 0.53
- SKYE 0.10
- MACD
- WYY -0.01
- SKYE 0.08
- Stochastic Oscillator
- WYY 59.89
- SKYE 74.31
About WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.